IntelGenx Technologies Corp (IGXT)

[BioSpecialist]

REASONS TO BUY THIS GOLDMINE .................

Market Cap laughable $45 Million / Monster Pipeline / Lots of News around the corner = LIFETIMER OPP HERE




Upcoming Milestones :

Big Partnership imminent :

•Announced a development and commercialization term sheet with a global pharmaceutical company for up to three products. If entered into, IntelGenx expects the definitive agreement to be finalized in the second quarter of 2016

Product :Rizaport (Migraine)
•European Mktg Approval–November 2015
•Planned USA submission to FDA Q4/2016
•Expected USA launch Q2/2017

Product :Tadalafil (Erectile Dysfunction) a better Oral thin-film version of Blockbuster Drug Cialis
•505(b)(2) USA NDA submission in Q4/2016
•Expected USA launch Q4/2017

Product :Indicated for Opioid Dependence
•Awaiting FDA approval
•According to IMS data, the oral film market for opioid dependence was worth more than $1.4B US in 2014.

IntelGenx Corp., today announced the recent initiation of a phase 1 clinical trial of montelukast, a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers disease, the most prominent form of dementia. IntelGenx expects results from the phase 1 trial to be available in September 2016.